Login / Signup

Drug-specific T-cell responses in patients with liver injury following treatment with the BACE inhibitor atabecestat.

Paul J ThomsonLaila KafuXiaoli MengJan SnoeysAn De BondtDries De MaeyerHans WilsLaurent LeclercqPetra VinkenDean John Naisbitt
Published in: Allergy (2020)
The detection of atabecestat metabolite-responsive T-cell clones activated via a pharmacological interactions pathway in patients with liver injury is indicative of an immune-based mechanism for the observed hepatic enzyme elevations.
Keyphrases
  • liver injury
  • drug induced
  • adverse drug
  • loop mediated isothermal amplification
  • emergency department
  • drug delivery
  • label free